Business
Time to debunk anti-vaxxer myths: CSL CEO – The Australian Financial Review
Demand for CSL’s core plasma products and surging government orders for flu vaccines has resulted in the biotech giant lifting the bottom end of its 2021 profit…
“We don’t have the ability to just turn on a dime and start making more flu vaccines … when we start the manufacturing process it’s pretty well done… and to turn and make more is very difficult late in the season, but we’ve had good yield
Continue Reading
-
Noosa News5 hours agoTeenage boy crashes into Ipswich home, left fighting for life in hospital
-
General11 hours agoUN special envoy Julie Bishop makes first trip to Myanmar after earthquake
-
General10 hours agoMatthew Dellavedova signs with the Sydney Kings as NBL free agency period continues
-
Noosa News13 hours agoCity of Moreton Bay throws homeless people’s tents into garbage trucks